Cardinal Biocraft develops advanced tools for understanding and engineering microbial cells. The company integrates synthetic biology and machine learning to rewire cellular functions. This platform enables the efficient production of novel molecules using engineered microbes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of microbial cell engineering for molecule production are often slow, inefficient, and rely heavily on trial-and-error. This makes it difficult to rapidly prototype and scale the production of novel, life-improving molecules using sustainable bio-manufacturing processes.
Solution
This startup offers a platform for engineering microbial cells by integrating synthetic biology, machine learning, and automation. This integrated approach enables rapid prototyping of microbial designs, allowing for faster iteration and optimization of molecule production. The platform aims to streamline the process of understanding, rewiring, and utilizing microbial cells to create a wide range of molecules for various applications. By leveraging machine learning, the platform can predict and optimize cell behavior, leading to more efficient and scalable bio-manufacturing solutions.
Target Audience
The primary target audience includes companies and researchers in the biotechnology, pharmaceutical, and industrial bio-manufacturing sectors seeking to accelerate the development and production of novel molecules using microbial cells.
Features
- Automated design and construction of synthetic DNA constructs for microbial engineering.
- Machine learning models to predict gene expression and metabolic flux in engineered cells.
- High-throughput screening and analysis of microbial phenotypes.
- Robotic automation for efficient cell culturing and sample preparation.
- Data analytics tools for visualizing and interpreting experimental results.